The company is strengthening its distribution network to ensure seamless access to its products
Globalpharma, the UAE’s leading pharmaceutical manufacturer and a wholly owned subsidiary of Dubai Investments, has unveiled its ambitious plans for 2025, marked by the launch of 25 innovative products across key therapeutic areas.
“Globalpharma’s growth and innovation perfectly align with Dubai Investments’ vision of driving transformation in key industries,” stated Mohammed Saeed Al Raqbani, General Manager, Dubai Investments Industries & Masharie and Board Director, Globalpharma. “As the pharmaceutical sector continues to grow, the Group is strategically positioning Globalpharma to capitalize on emerging opportunities,” he added.
Seamless access
As part of Globalpharma’s broader expansion efforts, the company is strengthening its distribution network to ensure seamless access to its products. By optimizing delivery channels and forging new partnerships, the company is focused on meeting the needs of healthcare practitioners (HCPs) and patients alike.
Additionally, Globalpharma is refining its market entry strategies to adapt to the unique requirements of regional markets, solidifying its presence in key territories while exploring new opportunities.
“Our strategic focus in 2025 revolves around innovation, accessibility, and partnerships. The launch of 25 new products across critical therapeutic areas underscores our commitment to meeting the region’s healthcare challenges,” concluded Basem Albarahmeh, General Manager, Globalpharma.
